Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$7.05 USD
-0.43 (-5.75%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $7.03 -0.02 (-0.28%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ATXS 7.05 -0.43(-5.75%)
Will ATXS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ATXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATXS
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy
Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade
ATXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Astria Therapeutics, Inc. (ATXS) Now Trades Above Golden Cross: Time to Buy?
Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?
Is Astria Therapeutics (ATXS) Stock Outpacing Its Medical Peers This Year?
Other News for ATXS
ATXS Fell Below 20 Day Moving Average on September 19
Pocket Pivot appears for ATXS after 1.22% move
Astria Therapeutics (ATXS) Receives a Buy from Jefferies
ATXS forms Pocket Pivot on September 17
Oppenheimer Sticks to Its Buy Rating for Astria Therapeutics (ATXS)